Conflict of Interest: Drs. Bigal and Walter are employees of Labrys Biologics, Inc. San Mateo, CA, USA. Dr. Rapoport is on the speaker's bureau of Allergan, Impax, and Nautilus Neurosciences. He is a consultant to Doctor Reddy's, Impax, Merck, Nautilus Neurosciences, NuPathe, Transcept, and Winston.
Calcitonin Gene-Related Peptide (CGRP) and Migraine Current Understanding and State of Development
Article first published online: 12 JUL 2013
© 2013 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 53, Issue 8, pages 1230–1244, September 2013
How to Cite
Bigal, M. E., Walter, S. and Rapoport, A. M. (2013), Calcitonin Gene-Related Peptide (CGRP) and Migraine Current Understanding and State of Development. Headache: The Journal of Head and Face Pain, 53: 1230–1244. doi: 10.1111/head.12179
- Issue published online: 10 SEP 2013
- Article first published online: 12 JUL 2013
- Manuscript Accepted: 7 JUN 2013
- calcitonin gene-related peptide;
- chronic migraine
Calcitonin gene-related peptide (CGRP) is a ubiquitous neuropeptide found at the very centers of the migraine process, both centrally and peripherally. It has been under careful study for approximately 25 years. Several CGRP-receptor antagonists are being evaluated for acute treatment of episodic migraine. Three monoclonal antibodies are being studied for prevention of episodic migraine, and 1 monoclonal antibody is being studied for prevention of chronic migraine. In this review, we discuss the role of CGRP in normal physiology and the consequences of CGRP inhibition for human homeostasis. We then review the current state of development for CGRP-receptor antagonists and CGRP monoclonal antibodies. We close by speculating on the potential clinical role of CGRP antagonism in the acute and preventive treatment of episodic and chronic migraine.